Step-by-Step Programs Offered from Basic AI New Drug Development
to Specialized SDL Self-Driving Lab Training

The AI New Drug Research Institute, an affiliate of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, announced on the 23rd that it will officially launch a full-cycle training system to cultivate professionals in AI new drug development.


Beginning with the introductory special lecture "AI New Drug Development Catch-up" on July 29, the association will sequentially operate various step-by-step programs throughout the year, ranging from basic AI new drug development education to specialized training in self-driving labs. These include a "Global SDL (Self-Driving Lab; AI-based autonomous laboratory) Introductory Special Lecture" with participation from world-renowned scholars on August 3.


This training is part of the "AI-Enabled New Drug Development Education and Promotion" project by the Ministry of Health and Welfare and the Korea Health Industry Development Institute.

AI Drug Development Catch-Up Training Poster. Korea Pharmaceutical and Bio-Pharma Manufacturers Association

AI Drug Development Catch-Up Training Poster. Korea Pharmaceutical and Bio-Pharma Manufacturers Association

View original image

As AI technology rapidly spreads across all stages of new drug development, there is a growing demand in the industry not only for researchers who understand AI, but also for specialists capable of designing and operating AI-based self-driving experiments.


To meet this demand, the association has established a step-by-step training system covering the entire process of AI new drug development. The plan is to enhance training effectiveness by linking introductory education covering fundamental concepts in AI new drug development, online learning, tailor-made courses for industry settings, boot camps, and Korea’s first SDL hands-on training center offering specialized self-driving lab training.


First, beginning July 29, the "AI New Drug Development Catch-up" course is an introductory program that presents the core concepts, latest technologies, and industrial applications of AI new drug development in a way that is accessible even to non-specialists. It will include sessions on paradigm shifts in new drug development and entry-level molecular dynamics (MD) practice, targeting not only pharmaceutical and biotech industry professionals, but also undergraduate and graduate students as well as beginner researchers in related fields.


Subsequent programs will include: ▲ "On-site AI New Drug Development Training" tailored to the specific research needs of each institution, ▲ an "AI New Drug Development Boot Camp" reflecting industry demand, and ▲ LAIDD (Lectures on AI-driven Drug Discovery), an online education platform offering stepwise learning paths — all of which form the foundation for hands-on and practical education activities available throughout the year.


The association also plans to significantly improve LAIDD this year to be even more learner-centered. A comprehensive learning roadmap will be established to support participants from introductory courses through to practical mastery, and there will be new features such as AI-driven personalized lecture recommendations and auto-captioning in 12 languages. The platform will also introduce practical content allowing non-specialists to directly execute key AI models without coding, as well as a curation function for important papers and models. Since its establishment in 2021, LAIDD has become Korea’s representative AI new drug development education platform, amassing over 12,000 cumulative users, with a particularly high proportion of industry professionals among its participants.


In August, full-fledged SDL education — specialized training in AI-based self-driving labs — will also begin. On August 3, the first program, "Global SDL Introductory Special Lecture," will feature Jason Hein, a world-renowned scholar in the field of SDL and professor at the University of British Columbia (UBC) in Canada. He will introduce SDL core concepts, the latest research trends, and the future of agent AI-based autonomous chemistry.


Following the initial special lecture, the program will proceed step by step with seminars sharing domestic and international SDL research case studies, experimental workflow design training, and implementation-focused hands-on sessions at Korea’s first-ever SDL training center.


Notably, this SDL training will be conducted at the AI new drug development SDL hands-on center, which the association established for the first time in Korea. Using automated reaction and analysis equipment as well as collaborative robots, the center will offer practical training replicating real research environments, such as color optimization, solubility scanning, and synthesis automation. In addition, joint training programs will be held in cooperation with Acceleration Consortium (AC) in Canada and the University of Toronto.



Standard Hee, head of the AI New Drug Research Institute, stated, "AI new drug development is a field that requires a breadth of expertise, ranging from a fundamental understanding of AI to the capability to implement real self-driving experiments. We are committed to fostering convergence-type talent who will lead the AI new drug development ecosystem by establishing a comprehensive training system — from basic courses that allow anyone to easily enter the field, to Korea's first SDL hands-on center and specialized education based on international collaboration."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing